Data / Form D filings / OptMed, Inc.
OptMed, Inc.: Form D filings
OptMed, Inc., a biotechnology company in New York, NY, filed 9 Form D notices with the SEC between 2009 and 2015. The latest, on August 11, 2015, reports $200,000 sold of a $500,000 offering to 1 investor.
Find out what OptMed, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 601 LEXINGTON AVENUE, SUITE 5100, New York, NY, 10022
- Phone
- (212) 867-4141
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1469988
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 11, 2015 | New notice | $500,000 | $200,000 | $300,000 | 1 | Jul 29, 2015 | sec.gov |
| Mar 17, 2015 | New notice | $400,000 | $200,000 | $200,000 | 3 | Mar 2, 2015 | sec.gov |
| Jun 27, 2014 | New notice | $1,500,000 | $75,000 | $1,425,000 | 1 | Jun 26, 2014 | sec.gov |
| Jun 11, 2013 | New notice | $1,200,000 | $124,000 | $1,076,000 | 4 | May 30, 2013 | sec.gov |
| Aug 22, 2012 | New notice | $2,100,000 | $257,321 | $1,842,679 | 8 | Aug 15, 2012 | sec.gov |
| Feb 3, 2012 | New notice | $2,000,000 | $321,849 | $1,678,151 | 4 | Jan 23, 2012 | sec.gov |
| Apr 29, 2011 | Amendment | $2,600,000 | $600,995 | $1,999,005 | 13 | Apr 15, 2011 | sec.gov |
| Apr 28, 2011 | New notice | $26,000,000 | $6,009,950 | $19,990,050 | 13 | Apr 15, 2011 | sec.gov |
| Sep 1, 2009 | New notice | $7,000,000 | $2,000,000 | $5,000,000 | 8 | Aug 21, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kevin McKim | Director | |
| Martin Sands | Director | |
| Ervin Braun | Executive Officer, Director | |
| Steven Sands | Director | |
| Sanket Parekh | Director | |
| Alain Klapholz | Executive Officer, Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Aug 10, 2015 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what OptMed, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.